Valeant buys back C$89.9 million three senior note series at discount

By Susanna Moon

Chicago, Nov. 19 - Valeant Pharmaceuticals International, Inc. said it repurchased a total of C$34.5 million principal amount of its 6½% senior notes due 2016 for C$34.3 million, a total of C$45.4 million principal amount of its 6 7/8% senior notes due 2018 for C$45.0 million and a total of C$10.0 million principal amount of its 7% senior notes due 2020 for C$9.5 million.

The company also bought back C$2.4 million principal amount of its 5.375% convertible notes for C$7.9 million.

The company's repurchase program began Nov. 15, and the company may make purchases of up to C$1.5 billion of its senior notes, common shares or other debt. The currrent program replaces the company's program that expired on Nov. 7.

Valeant is a Mississauga, Ont.-based specialty pharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.